Although we identified ACE2 as an important mediator of reduced intrinsic ACE activity in severe COVID-19, a significant portion of this reduction remained unaccounted for, and alternative pathways of angiotensin II degradation or endogenous ACE inhibition should be sought in subsequent studies. The gene discussed is AGT; the disease is COVID-19.